Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475847 | 1.00 | KMT2A (0.75) | KMT2ASLC6A4OPRM1SLC6A2SLC6A3 | |
| SCHEMBL5475198 | 0.92 | KMT2A (0.77) | KMT2ASLC6A4OPRM1SLC6A2SLC6A3 | |
| SCHEMBL5469097 | 0.91 | KMT2A (0.64) | KMT2ASLC6A4SLC6A2SLC6A3SIGMAR1 | |
| SCHEMBL5469094 | 0.91 | KMT2A (0.64) | KMT2ASLC6A4SLC6A2SLC6A3SIGMAR1 | |
| SCHEMBL5482311 | 0.88 | KMT2A (0.61) | KMT2ASLC6A4SLC6A2SLC6A3SIGMAR1 | |
| SCHEMBL5469632 | 0.88 | KMT2A (0.61) | KMT2ASLC6A4SIGMAR1PDCD1CD274 | |
| SCHEMBL5469627 | 0.88 | KMT2A (0.61) | KMT2ASLC6A4SIGMAR1PDCD1CD274 | |
| SCHEMBL5482313 | 0.88 | KMT2A (0.61) | KMT2ASLC6A4SLC6A2SLC6A3SIGMAR1 | |
| SCHEMBL5772537 | 0.88 | KMT2A (0.61) | KMT2ASLC6A4SLC6A2SLC6A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL4876770 | 0.87 | KMT2A (0.60) | KMT2ASLC6A4OPRM1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679069-A1 | NOVEL PIPERIDINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | LDLR, PRMT5, MSR1 | KMT2A 1301/4885SLC6A4 2414/4885OPRM1 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.